Improvement in symptoms of anxiety and depression in patients with atopic dermatitis after treatment with baricitinib

J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e147-e150. doi: 10.1111/jdv.17704. Epub 2021 Oct 2.

Authors

J P Thyssen¹, P Lio², S Ball³, E Pierce³, L Sun³, Y Chen³, J K L Tan⁴, M Augustin⁵

Affiliations

¹ Department of Dermatology and Venereology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
² Medical Dermatology Associates of Chicago, Chicago, IL, USA.
³ Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
⁴ University of Western Ontario and Windsor Clinical Research Inc., Windsor, ON, Canada.
⁵ University Medical Centre Hamburg, Hamburg, Germany.

PMID: 34553429
DOI: 10.1111/jdv.17704

No abstract available

Publication types

Letter

MeSH terms

Anxiety / drug therapy
Azetidines*
Depression / drug therapy
Depression / etiology
Dermatitis, Atopic* / complications
Dermatitis, Atopic* / drug therapy
Humans
Purines
Pyrazoles
Sulfonamides

Substances

Azetidines
Purines
Pyrazoles
Sulfonamides
baricitinib

Grants and funding

Eli Lilly and Company